Lincoln Capital Corp Acelrx Pharmaceuticals Inc Transaction History

Lincoln Capital Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 05, 2021	SELL	$1.18 - $1.98 $65,554 - $109,998	-55,555 Closed	0 $0
Q3 2020 Nov 04, 2020	BUY	$1.01 - $1.81 $5,610 - $10,054	5,555 Added 11.11%	55,555 $79,000
Q2 2020 Jul 22, 2020	BUY	$1.03 - $1.69 $10,300 - $16,900	10,000 Added 25.0%	50,000 $61,000
Q1 2020 Apr 16, 2020	SELL	$0.76 - $2.07 $12,920 - $35,190	-17,000 Reduced 29.82%	40,000 $47,000
Q4 2019 Jan 17, 2020	SELL	$1.66 - $2.4 $16,600 - $24,000	-10,000 Reduced 14.93%	57,000 $120,000
Q2 2019 Jul 12, 2019	BUY	$2.1 - $3.93 $10,500 - $19,650	5,000 Added 8.06%	67,000 $170,000
Q4 2018 Jan 22, 2019	SELL	$2.13 - $4.8 $1,650 - $3,720	-775 Reduced 1.23%	62,000 $143,000
Q3 2018 Oct 10, 2018	BUY	$2.6 - $4.6 $74,165 - $131,215	28,525 Added 83.28%	62,775 $242,000
Q2 2018 Jul 26, 2018	BUY	$2.13 - $4.2 $29,820 - $58,800	14,000 Added 69.14%	34,250 $116,000
Q1 2018 Apr 12, 2018	BUY	$1.7 - $2.35 $425 - $587	250 Added 1.25%	20,250 $42,000
Q3 2017 Oct 18, 2017	BUY	$2.9 - $4.6 $58,000 - $92,000	20,000	20,000 $92,000

Ticker ACRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 7,366,600
Market Cap $8.32M
Description
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...

Get notified when there are updates to the investment portfolio of Lincoln Capital Corp, based on Form 13F filings with the SEC.

Stay updated on Lincoln Capital Corp with notifications on news.